英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

yaks    

请选择你想看的字典辞典：
单词字典翻译
yaks查看　yaks　在百度字典中的解释百度英翻中〔查看〕
yaks查看　yaks　在Google字典中的解释Google英翻中〔查看〕
yaks查看　yaks　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ESR1-mutated, ER+ HER2- mBC Treatment | ORSERDU® (elacestrant)
    INDICATION ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
  • EMERALD Trial for ESR1-Mutations | ORSERDU® (elacestrant)
    INDICATION ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
  • U. S. FDA approves Inluriyo (imlunestrant) for adults with ER+ . . .
    Inluriyo is a treatment for ER+, HER2–, ESR1 -mutated MBC Some breast cancers develop ESR1 mutations that can cause estrogen receptors to become overactive and drive cancer growth
  • Inluriyo: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Inluriyo is used to treat adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy Inluriyo (imlunestrant) is an oral SERD (selective estrogen receptor degrader) taken once a day Includes Inluriyo side effects, warnings, and clinical trial results
  • FDA approves elacestrant for ER-positive, HER2-negative, ESR1 . . .
    On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc ) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1
  • HCP Home | Inluriyo™ (imlunestrant)
    Indication Inluriyo ™ is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy 1
  • ELEVATE Trial: Elacestrant Combos Boost PFS in ER+ HER2 . . .
    Study Rationale In January 2023, the FDA approved elacestrant for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy 2
  • label - accessdata. fda. gov
    INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
  • Orserdu Approved for ER-Positive, HER2-Negative, ESR1-Mutated . . .
    The FDA has approved elacestrant (Orserdu, Stemline Therapeutics) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy A link to this article will be included in this email
  • Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 . . .
    U S Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy





中文字典-英文字典  2005-2009